BACKGROUND/ PURPOSE: The aim of this report was to assess the outcome of aggressive surgical treatment for intrahepatic cholangiocarcinoma. METHODS: From 1984 to 2001, we encountered 64 patients with intrahepatic cholangiocarcinoma. Of the 64 patients, 50 patients who underwent surgical resection with macroscopically curative objectives (78%) were reviewed for surgical procedures and outcomes. RESULTS: Hemi- or more extensive hepatectomy was required for surgical resection in 40 patients (80%). Overall hospital morbidity and mortality rates were 50% and 8%, respectively. Curative resection with pathological free margins was achieved in 34 patients (68%). The 1-, 3-, and 5-year patient survival and tumor-free survival rates were 61.6%, 37.6%, and 22.5%; and 55%, 11%, and 11%, respectively. Among the macroscopic types, all 9 patients with intraductal growth type are alive 11-75 months after surgery. Survival rates among patients who had undergone curative resection were significantly better than those in patients who had undergone noncurative resection, even when patients with the intraductal growth type were excluded. Nodal status did not affect patient survival. CONCLUSIONS: Although the overall survival rate after surgical resection remains unsatisfactory, long-term survival is possible through extended surgical resection with pathological free margins. Patients with the intraductal growth type of intrahepatic cholangiocarcinoma might have the best chance of being cured by surgical treatment.
BACKGROUND/ PURPOSE: The aim of this report was to assess the outcome of aggressive surgical treatment for intrahepatic cholangiocarcinoma. METHODS: From 1984 to 2001, we encountered 64 patients with intrahepatic cholangiocarcinoma. Of the 64 patients, 50 patients who underwent surgical resection with macroscopically curative objectives (78%) were reviewed for surgical procedures and outcomes. RESULTS: Hemi- or more extensive hepatectomy was required for surgical resection in 40 patients (80%). Overall hospital morbidity and mortality rates were 50% and 8%, respectively. Curative resection with pathological free margins was achieved in 34 patients (68%). The 1-, 3-, and 5-year patient survival and tumor-free survival rates were 61.6%, 37.6%, and 22.5%; and 55%, 11%, and 11%, respectively. Among the macroscopic types, all 9 patients with intraductal growth type are alive 11-75 months after surgery. Survival rates among patients who had undergone curative resection were significantly better than those in patients who had undergone noncurative resection, even when patients with the intraductal growth type were excluded. Nodal status did not affect patient survival. CONCLUSIONS: Although the overall survival rate after surgical resection remains unsatisfactory, long-term survival is possible through extended surgical resection with pathological free margins. Patients with the intraductal growth type of intrahepatic cholangiocarcinoma might have the best chance of being cured by surgical treatment.
Authors: Renumathy Dhanasekaran; Alan W Hemming; Ivan Zendejas; Thomas George; David R Nelson; Consuelo Soldevila-Pico; Roberto J Firpi; Giuseppe Morelli; Virginia Clark; Roniel Cabrera Journal: Oncol Rep Date: 2013-02-18 Impact factor: 3.906
Authors: Roman Kloeckner; Christian Ruckes; Kai Kronfeld; Marcus Alexander Wörns; Arndt Weinmann; Peter Robert Galle; Hauke Lang; Gerd Otto; Waltraud Eichhorn; Mathias Schreckenberger; Christoph Dueber; Michael Bernhard Pitton Journal: Trials Date: 2014-08-06 Impact factor: 2.279